City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) Director Robert Nelsen acquired 170,000 shares of City Therapeutics stock in a transaction that occurred on Monday, October 19th. The stock was bought at an average cost of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director directly owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
City Therapeutics Stock Performance
Shares of CTY stock opened at $20.43 on Thursday. City Therapeutics, Inc. has a 1 year low of $19.97 and a 1 year high of $23.88.
About City Therapeutics
Further Reading
- Five stocks we like better than City Therapeutics
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
